Aldesleukin · Proleukin, ILT-101

What is Aldesleukin?

Aldesleukin is a recombinant human interleukin-2 that binds and activates the IL-2 receptor, promoting lymphocyte proliferation and cytotoxicity, LAK and NK cell activation, and interferon-gamma production.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Proleukin, ILT-101, Recombinant Human Interleukin-2

Drug type

Recombinant protein

Targets

Interleukin-2 receptor (IL2RA)

Mechanism

Immune activation, directed at Interleukin-2 receptor (IL2RA)

Pathways

JAK3 activation, STAT5 signaling, lymphocyte proliferation, NK cell activation

Therapy area

Oncology

Developer

Chiron

In trials of

CELU

FDA status

Approved as Proleukin (May 5, 1992), BLA103293 · FDA label

UNII

M89N0Q7EQR

✅ FDA-approved uses

• Metastatic renal cell carcinoma
• Metastatic melanoma

From the indications section of the FDA label (version of Dec 20, 2024). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic HER2 Positive Gastroesophageal Junction Cancer

Other drugs acting on IL2RA

Sources

• FDA Purple Book
• FDA label (DailyMed)
• FDA label Proleukin (2024-12-20), indications
• NCI Thesaurus
• ClinicalTrials.gov NCT05207722

Updated Oct 3, 2026.